Klin Farmakol Farm. 2011;25(3):144-149

Ertapenem and his position among other carbapenems

Jiří Beneš
Klinika infekčních nemocí 3. LF UK, FN Na Bulovce, Praha

Ertapenem belongs to carbapenem antibiotics. Nevertheless it differs from other carbapenems registered in the Czech Republic (imipenem,

meropenem, doripenem) in two important features: (a) low efficacy against Pseudomonas aeruginosa a Acinetobacter spp.; thus

ertapenem is predestined for treatment community-acquired infections rather than nosocomial infections; (b) relatively long half-time

that enables once daily dosing. Thus, ertapenem is a good choice for treatment of mixed community-acquired infections and/or for

treatment of infections caused by E. coli, Klebsiella spp., or other bacteria producing extended-spectrum beta-lactamases (ESBL, AmpC).

The long half-time make ertapenem very useful for out-patient therapy and home care.

Keywords: ertapenem, carbapenems, half-time

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Beneš J. Ertapenem and his position among other carbapenems. Klin Farmakol Farm. 2011;25(3):144-149.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chambers HF. Carbapenems and monobactams. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010: 341-5. Go to original source...
    2. Finch RG, Greenwood D, Norrby SR, Whitley RJ (eds). Antibiotic and Chemotherapy. 8th ed. Philadelphia: Churchill Livingstone, 2003: 265-70.
    3. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-52. Go to original source... Go to PubMed...
    4. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-44. Go to original source... Go to PubMed...
    5. Invanz. Product information. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000389/WC500033921.pdf.
    6. Legua P, Lema J, Moll J, et al. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin Ther 2002; 24: 434-444. Go to original source... Go to PubMed...
    7. Majumdar AK, Musson DG, Birk KL, et al. Pharmakokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-3511. Go to original source... Go to PubMed...
    8. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al. A sudy evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34: 1076-1083. Go to original source... Go to PubMed...
    9. Vetter N, Cambronero-Hernandez E, Rohlf J, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 1770-1785. Go to original source... Go to PubMed...
    10. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-1468. Go to original source... Go to PubMed...
    11. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-1703. Go to original source... Go to PubMed...
    12. Yellin AE, Hassett JM, Fernandez A, et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intraabdominal infections in adults. Intern J Antimicrob Agents 2002; 20: 165-173. Go to original source... Go to PubMed...
    13. Solomkin JS, Yellin AE, Rotstein OD. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2003; 237: 235-245. Go to original source... Go to PubMed...
    14. Roy S, Higareda I, Angel-Muller E, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003; 11: 27-37. Go to original source... Go to PubMed...
    15. Tomera KM, Burdmann EA, Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002; 46: 2895-2900. Go to original source... Go to PubMed...
    16. Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002; 60: 16-22. Go to original source... Go to PubMed...
    17. Isaacs R, Teppler H, Friedland IR, et al. Ertapenem (ERT) for treatment of bacteremia. In: Program and Abstracts of the 42nd ICAAC, San Diego, USA. Abstract L-380, p 347.
    18. Itani KMF, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxix in elective colorectal surgery. N Engl J Med 2006; 355: 2640-2651. Go to original source... Go to PubMed...
    19. European Centre for Diseases prevention and Control: Antimicrobial resistance surveillance in Europe. 2009. http://ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf.
    20. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-542. Go to original source... Go to PubMed...
    21. Koga T, Masuda N, Kakuta M, et al. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 2849-2854. Go to original source... Go to PubMed...
    22. Koblihová H, Suchopár J. Karbapenemy: přehled a porovnání základních údajů. Remedia 2008; 18: 247-251.
    23. Doribax. Product information. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000891/WC500037148.pdf.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.